
Loading, please wait...

Loading, please wait...

This randomized trial evaluated neoadjuvant immune checkpoint blockade in 63 patients with surgically resectable recurrent glioblastoma; 58 received study treatment. Patients received nivolumab + ipilimumab, nivolumab alone, or placebo before surgery. The primary endpoint was met: dual checkpoint blockade significantly increased tumor-infiltrating lymphocyte (TIL) density versus untreated control. Median overall survival was 402 days (95% CI, 265–571) among patients assigned to dual ICB versus 273 days (95% CI, 166–506) with nivolumab alone. Dual ICB also produced robust intratumoral and systemic immune activation, including increased interferon-related gene expression in blood. Higher TIL density and early systemic interferon-signature induction were associated with improved survival, whereas tumor mutational burden was not. No unanticipated toxicities were observed.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This randomized trial evaluated neoadjuvant immune checkpoint blockade in 63 patients with surgically resectable recurrent glioblastoma; 58 received study treatment. Patients received nivolumab + ipilimumab, nivolumab alone, or placebo before surgery. The primary endpoint was met: dual checkpoint blockade significantly increased tumor-infiltrating lymphocyte (TIL) density versus untreated control. Median overall survival was 402 days (95% CI, 265–571) among patients assigned to dual ICB versus 273 days (95% CI, 166–506) with nivolumab alone. Dual ICB also produced robust intratumoral and systemic immune activation, including increased interferon-related gene expression in blood. Higher TIL density and early systemic interferon-signature induction were associated with improved survival, whereas tumor mutational burden was not. No unanticipated toxicities were observed.
2 months ago

Researchers have identified compound 8g, an orally bioavailable corydamine derivative that targets glutathione reductase. By dismantling redox defenses and disrupting NADPH homeostasis, 8g acts synergistically with sorafenib to trigger apoptosis and overcome drug resistance in hepatocellular carcinoma models.
Yesterday

A breakthrough blood test measuring the RNA biomarker Tu-Stroma detects microscopic serous tubal intraepithelial carcinoma (STIC) lesions with remarkable accuracy. This non-invasive diagnostic tool offers crucial biological insight to guide prophylactic surgery decisions for women carrying high-risk genetic mutations.
2 days back

Researchers have engineered novel light-on photoswitchable adrenoceptor agonists targeting β1-receptors. By remaining inactive until illuminated, these precision molecules offer reversible optical control, tailored relaxation kinetics, and distinct efficacy profiles, paving the way for targeted cardiovascular therapies.
Yesterday

A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 weeks back

A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 weeks back